Siloam Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 28.55%
(FY 2023)
- Profit 112.07%
(FY 2023)
- Ebitda 161.94%
(FY 2023)
- Net Worth 4.96%
(FY 2023)
- Total Assets 229.07%
(FY 2023)
About Siloam Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Yuvaraj Venkatesan, Rajan Gnanaprakasam, Balamurugan, and One other member serve as directors at the Company.
- CIN/LLPIN
U24303TN2019PTC132661
- Company No.
132661
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Nov 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Siloam Pharmaceuticals Private Limited offer?
Siloam Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Capsules, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Hand Sanitizers & Personal Hygiene, Antiseptic Liquid & Cream, Arthritic Drugs, Nasal Drops, Nutraceuticals & Dietary Supplements, Mineral Supplement.
Who are the key members and board of directors at Siloam Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jamespremkumar Jamespremkumar  | Managing Director | 19-Nov-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Yuvaraj Venkatesan | Director | 19-Nov-2019 | Current |
| Rajan Gnanaprakasam | Director | 19-Nov-2019 | Current |
| Balamurugan | Whole-Time Director | 19-Nov-2019 | Current |
Financial Performance of Siloam Pharmaceuticals.
Siloam Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.55% increase. The company also saw a substantial improvement in profitability, with a 112.07% increase in profit. The company's net worth moved up by a moderate rise of 4.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Siloam Pharmaceuticals?
In 2023, Siloam Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Timon Pharmaceuticals Private LimitedActive 10 years 9 monthsJamespremkumar Jamespremkumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Siloam Pharmaceuticals?
Siloam Pharmaceuticals has a workforce of 24 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Siloam Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Siloam Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
